发明公开
EP3177921A1 METHODE DE DETERMINATION DU PROFIL DE STRUCTURE D'UN CAILLOT DE FIBRINE REFLETANT SA STABILITE, POUR PREDIRE LE RISQUE DE SAIGNEMENT, DE THROMBOSE OU DE RE-THROMBOSE
审中-公开
程序用于确定结构体轮廓的纤维蛋白凝块作为预测出血风险的IT稳定性的一种表达,血小板血栓形成或血栓重新的
- 专利标题: METHODE DE DETERMINATION DU PROFIL DE STRUCTURE D'UN CAILLOT DE FIBRINE REFLETANT SA STABILITE, POUR PREDIRE LE RISQUE DE SAIGNEMENT, DE THROMBOSE OU DE RE-THROMBOSE
- 专利标题(英): Method for determining the structural profile of a fibrin clot reflecting the stability thereof, in order to predict the risk of bleeding, thrombosis or rethrombosis
- 专利标题(中): 程序用于确定结构体轮廓的纤维蛋白凝块作为预测出血风险的IT稳定性的一种表达,血小板血栓形成或血栓重新的
-
申请号: EP15754272.1申请日: 2015-07-24
-
公开(公告)号: EP3177921A1公开(公告)日: 2017-06-14
- 发明人: CONTANT, Geneviève , POLACK, Benoît , CATON, François , DASSI, Carhel
- 申请人: Diagnostica Stago , Centre National de la Recherche Scientifique (C.N.R.S.) , Université Grenoble Alpes , Centre Hospitalier Universitaire Grenoble
- 申请人地址: 3 Allée Theresa 92600 Asnières-sur- Seine FR
- 专利权人: Diagnostica Stago,Centre National de la Recherche Scientifique (C.N.R.S.),Université Grenoble Alpes,Centre Hospitalier Universitaire Grenoble
- 当前专利权人: Diagnostica Stago,Centre National de la Recherche Scientifique (C.N.R.S.),Université Grenoble Alpes,Centre Hospitalier Universitaire Grenoble
- 当前专利权人地址: 3 Allée Theresa 92600 Asnières-sur- Seine FR
- 代理机构: Cabinet Plasseraud
- 优先权: FR1457219 20140725
- 国际公布: WO2016012729 20160128
- 主分类号: G01N33/49
- IPC分类号: G01N33/49
摘要:
The present invention relates to a method for dynamically determining the structural profile of a fibrin clot, reflecting the stability thereof in a biological sample of a patient, said method comprising the following steps: a) mixing the undiluted biological sample with tissue factor or a mixture of tissue factor and tissue plasminogen activator; b) incubating the mixture obtained in step a), then adding calcium ions to the mixture obtained, in order to initiate the formation of a fibrin clot; c) measuring the turbidity or the optical density of the clot being formed in step b), at at least two wavelengths of between 450 nm and 850 nm, and for a time of between 1 and 35 minutes; d) determining the structural profile of the analysed clot, expressed as a number of protofibrils, density and radius in c) by means of the formula τ.λ
5 = A [Fg].(λ
2 - B), wherein τ is the turbidity of the clot at a given wavelength λ, [Fg] is the initial weight concentration of fibrinogen, and A and B are coefficients which are proportional, respectively, to the density and the radius of the fibres that make up the clot; and e) comparing the obtained profile with a control. The method preferably includes a step f) that makes it possible to predict the risk of bleeding, thrombosis or rethrombosis and to select the anticoagulant that is best suited to the clinical situation of a patient.
5 = A [Fg].(λ
2 - B), wherein τ is the turbidity of the clot at a given wavelength λ, [Fg] is the initial weight concentration of fibrinogen, and A and B are coefficients which are proportional, respectively, to the density and the radius of the fibres that make up the clot; and e) comparing the obtained profile with a control. The method preferably includes a step f) that makes it possible to predict the risk of bleeding, thrombosis or rethrombosis and to select the anticoagulant that is best suited to the clinical situation of a patient.
信息查询